GlaxoSmithKline says it nailed the primary endpoint in a Phase III study of its injectable IL-5 drug mepolizumab, beating out a placebo with statistically significant results for severe eosinophilic asthma and setting the stage for the first regulatory filings for the drug.

…read more

Source: GlaxoSmithKline maps a route to regulators with positive PhIII asthma data